Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| For a small biotechnology company, we have tremendous amount of opportunity to build shareholder value arriving in the near-term |
| I'm incredibly proud of our team, our collaborators, and partners and most of all, the patients, who have made such an important contribution to these efforts |
| In the next several months, we expect to see multiple efforts at NRx come to fruition, which we believe may provide significant upside to our investors |
| We've worked with Nephron and stationery founder and owner, Lou Kennedy on previous projects and have great confidence in the Nephron team |
| That investment paid off for the substantial acceleration in our enrollment rate over the past quarter, a capability that will serve us well should the drug demonstrate efficacy in this upcoming readout |
| Achieving any one of those catalysts has the potential to unlock substantial shareholder value |
| Our success on more than one front has the potential to unlock exponential growth |
| I'm incredibly proud of our team, our collaborators, and partners, and most of all, the patients who have made such an important contribution to these efforts |
| And that's why, in our view, the most attractive opportunity for our current shareholders is to create these spin-offs where we've already seen appetite from new investors to come in, help fund the spin-offs, but do it in a way that current investors will benefit in proportion to their current shareholder |
| The company solidified its working relationship with Alvogen over the last quarter we've begun working in unison to plan the final development and commercialization of NRX-101 |
| So there are enormously attractive opportunities for shareholders and at the same time, creating dilution within the core company wouldn't make all that much sense for shareholders |
| Very good |
| We believe that NRX-101 as an oral medicine has the potential to demonstrate benefit in patients who would otherwise require intravenous third and fourth-generation antibiotics |
| Third, our program to seek a new drug approval for intravenous ketamine, which we have designated as NRX-100, and established that drug in a new firstly-capitalized company that aims to be cash flow positive by year-end 2024 |
| Should the company succeed in serving 10% of the cUTI market we believe the revenue from NRX-101 for this indication has the potential to reach hundreds of millions of dollars annually based on 3 million cases per year in the US |
| As you've seen in our presentations, the findings of the trial demonstrated overwhelmingly positive, statistically significant reduction in both suicidality, the primary endpoint of the trial and depression to secondary end point, among patients treated with intravenous ketamine compared to those treated with placebo |
| And here it is the Department of Defense study in pain is positive |
| Product stability work has continued to support the targeted two-year plus shelf life at potential drug launch |
| All of us at NRX are deeply grateful to the many shareholders who have reached out to us, encouraged us, and supported us for a period of immense challenge in the biotechnology market |
| The company has been advised by counsel that this action has resulted in positive share action in the past when implemented by other issuers of NASDAQ stock |
| Should these trial results support efficacy of DCS, in the treatment of chronic pain vaccine, the results are expected to provide a breakthrough therapy path for treatment of chronic pain with D-cycloserine and DCS containing medicines |
| Is IV ketamine really that much better than inhaled? Jonathan Javitt Well, we know from extensive literature and now from two well controlled randomized prospective trials and IV ketamine works against acute suicidality |
| And fourth, the near-term approval of our investigational new drug application and award of qualified infectious disease product classification to NRX-101 in complicated urinary tract infection, which is called CUTI |
| Our clinical experience in psychiatry suggests that the lurasidone component of NRX-101, blocks unwanted CNS side effects and unlocks the potential of D-cycloserine to treat antibiotic-resistant, urinary tract infections with a decreased propensity to cause unwanted CNS effects |
| Thank you and I wish you guys good luck |
| What do you see as the clinical and regulatory pathway for NRX-101 in pain? Jonathan Javitt Well, we've already filed an investigational new drug application with the FDA for the use of NRX-101 in pain and received an enthusiastic response or response that we've seen is enthusiastic from the FDA Division of Anesthesia, analgesia and addiction products, which is a division that regulates pain products |
| As those milestones play out, we will continue to act in a manner that is most supportive of our shareholders |
| And NRX-101 has the potential to be the first NMDA antagonist drug to seek approval for this indication |
| In 2015, DCS was demonstrated to be effective against pathogens that are increasingly like it across sepsis and increasingly resistant to first and second line antibiotics |
| When we met with FDA in January 2023, the agency strongly encouraged us to develop Ketamine as a label drug, rather than rely on prior stabilization of Suicidality and depression, that's achieved through the common clinical practice through today's clinical practice of infusing generic Ketamine that's compounded in licensed pharmacies |
| Statement |
|---|
| So nasal ketamine has a history of disappointing industry |
| Over the past year, several clinical trials of promising investigational medicine for depression have failed |
| Unfortunately, the intranasal drug failed two months ago in clinical trials in patients for suicidal ideation |
| We await data from Northwestern University's Department of Defense funded trial in chronic pain |
| In 2006, there was a major failure associated with the clinical trial for nasal ketamine and treatment of chronic pain |
| Investors have expressed some concern about whether we will maintain compliance with NASDAQ listing requirements |
| Investors have contacted us with the belief that the company's share price may be adversely affected by short sales of stock that may frequently accompany positive news |
| Intranasal Ketamine previously failed for the treatment of chronic pain in 2006 |
| Importantly, a recent federal court decision holds brokerages liable for damages to companies associated with persistent naked short positions |
| These types of [indiscernible] fell out of favor as antibiotic in the 1970s because of the CNS effects caused by NMDA blocking properties and because of the widespread availability of effective first and second-generation antibiotics |
| Finally, I'd like to address a challenging issue, it's frequently raised with us by investors |
| There's an acute public health need for a safely manufactured diversion and abuse resistant form of ketamine, particularly in light of drug shortages caused by newly and appropriately rigorous FDA manufacturing standards |
| Indeed, Phase 3 biotechnology products are often delayed by unexpected manufacturing failures, perhaps more often than by unexpected clinical trial results |
| In other words, steps that originates in the urinary tract has resulted in a marked increase in complicated urinary tract infection, hospitalization and death from urosepsis |
| The challenge we faced in responding to FDA's guidance, is that a definitive trial of IV Ketamine in large numbers of patients with acute Suicidality is far more complex and expensive things could be achieved by a small company such as ours |
| In recent years, increased antibiotic resistance to common pathogens that cause urinary tract infections on urosepsis |
| It still has to beat the standard of care |
| Second, the near-term readout of the Department of Defense funded clinical trial of D-cycloserine for chronic pain |
| Finally, we expect that our focus on urinary tract infection is a bit surprising, given our identity as a CNS for this company |
| And in health ketamine has never demonstrated that in a large multi-center trial |
Please consider a small donation if you think this website provides you with relevant information